Age-related macular degeneration

Prime Editing (PE5max/PEmax) via Dual-AAV delivery is a rationale-driven therapeutic strategy for Age-related macular degeneration targeting the CFH c.3643C>G (p.Arg1215Gly) variant (Pathogenic, missense variant). The editing system (PEmax with engineered pegRNA) search-and-replace editing that directly rewrites the pathogenic transversion back to wild-type without requiring DSBs. Target tissue: Eye/Retina. Therapeutic goal: Correct CFH rs1061170 (Y402H) missense variant at chr1:196690107 to restore normal complement regulation in retina and prevent AMD progression. Risk profile: off-target Low (prime editing has inherently low off-target rate), delivery complexity Medium, immunogenicity High.

1. Molecular basis: CFH NM_000186.4(CFH):c.3643C>G (p.Arg1215Gly) is classified as Pathogenic (ClinVar variation ID 16542). Molecular consequence: missense variant. Protein change: R1215G. 2. Epidemiology: Affects approximately 200 million people worldwide, prevalence increasing to 288 million by 2040. Higher prevalence in European ancestry populations with 30-40% carrying risk allele. 3. Standard of care: Anti-VEGF therapy for wet AMD (ranibizumab, aflibercept, bevacizumab) requiring frequent injections; newly approved complement inhibitors for geographic atrophy (pegcetacoplan, avacincaptad); nutritional supplements (AREDS2). 4. Pipeline: Multiple gene therapy approaches in clinical development (AAV-based anti-VEGF delivery), CRISPR editing in Phase I/II trials for retinal disorders, complement inhibitors in Phase III for geographic atrophy. 5. Prime editing validation: PEmax (Chen et al. 2021, Cell) enables precise insertions, deletions, and all 12 point mutations without DSBs. Prime Medicine is advancing PE programs into clinical development. LNP and dual-AAV delivery of PE have been demonstrated in preclinical liver and CNS models.

1. No published data specifically correcting CFH c.3643C>G (p.Arg1215Gly) with Prime Editing (PE5max/PEmax); strategy is based on general principles and must be validated preclinically. 3. Dual-AAV delivery requires intein-mediated protein reconstitution with lower efficiency than single-AAV. Pre-existing AAV immunity in the patient population may limit eligibility. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

For the rare, highly penetrant CFH c.1873G>T (p.Glu625Ter) nonsense variant — which eliminates the C-terminal complement C3b/polyanion-binding domains essential for local complement regulation on retinal surfaces — subretinal AAV-mediated delivery of a functional CFH transgene represents a rational gene supplementation strategy. Unlike the common CFH Y402H risk variant (which modestly increases AMD risk in a polygenic context), this loss-of-function variant causes severe complement dysregulation and may respond to gene replacement restoring local CFH expression in the RPE/subretinal space.

Complement Factor H (CFH) is the principal fluid-phase and surface-bound regulator of the alternative complement pathway. It contains 20 short consensus repeat (SCR) domains; the C-terminal SCR19-20 domains mediate binding to host cell surfaces via C3b and glycosaminoglycans. The p.Glu625Ter variant truncates CFH within SCR10, eliminating SCR11-20 and ablating surface-recognition capacity while potentially preserving some fluid-phase C3b cofactor activity (SCR1-4). Gyroscope Therapeutics (now Novartis) developed GT005, a subretinal AAV2-based vector expressing Complement Factor I (CFI, a related complement regulator), which completed Phase I/II trials (NCT03846193) for geographic atrophy AMD. An analogous approach delivering CFH directly to RPE cells could restore local complement regulation at Bruch membrane, where complement activation drives drusen formation and RPE atrophy. Apellis pegcetacoplan (Syfovre, intravitreal C3 inhibitor) and Iveric Bio avacincaptad pegol (Izervay, intravitreal C5 inhibitor) are approved complement-targeted therapies for GA, validating complement as a druggable pathway in AMD.

Most AMD is polygenic with small effect sizes from multiple complement and non-complement loci — gene therapy targeting CFH alone may not suffice for typical AMD. However, the p.Glu625Ter variant is a rare, high-impact allele where monogenic complement dysregulation is the primary driver, making it a better candidate for gene replacement than common-variant AMD. AAV-CFH transgene must produce secreted CFH that reaches the subretinal/Bruch membrane compartment at sufficient concentrations. CFH is a large protein (155 kDa, ~3.7 kb CDS), which fits within AAV capacity but leaves limited room for regulatory elements. No clinical trial specifically testing AAV-CFH gene delivery for AMD has been registered. The natural history of CFH loss-of-function variants in AMD is not as well characterized as for atypical hemolytic uremic syndrome (aHUS), where CFH mutations are better studied.

For CFH c.2596+1G>C, a pathogenic splice donor variant that disrupts complement factor H production and leads to uncontrolled alternative complement pathway activation in the retina, anti-complement antibody and aptamer therapies represent the first FDA-approved treatments for geographic atrophy (GA), the advanced form of dry AMD. Pegcetacoplan (Syfovre, Apellis, anti-C3) and avacincaptad pegol (Izervay, Astellas, anti-C5) received FDA approval in 2023 for GA secondary to AMD. CFH loss-of-function variants like c.2596+1G>C cause constitutive overactivation of complement C3 convertase on retinal surfaces, leading to membrane attack complex deposition and progressive RPE/photoreceptor death. Complement inhibition directly addresses this pathogenic mechanism.

The OAKS and DERBY Phase 3 trials for pegcetacoplan (intravitreal anti-C3 cyclic peptide-PEG conjugate) demonstrated significant reduction in GA lesion growth rate vs sham: 22% reduction at 24 months (monthly dosing) in pooled analysis. The GATHER2 Phase 3 trial for avacincaptad pegol (intravitreal C5 inhibitor) showed 18% reduction in GA growth at 12 months. For patients with rare CFH loss-of-function variants (as opposed to the common Y402H risk polymorphism), the complement dysregulation is more severe and genetically defined, potentially predicting stronger treatment responses — though no variant-stratified efficacy data have been published. Genetic studies confirm that CFH loss-of-function (including splice-site variants) is associated with earlier onset, more aggressive GA progression, and higher complement biomarker levels (elevated Ba, C3a, C5a in aqueous humor). The anti-C5 antibody eculizumab has shown efficacy in CFH-related atypical hemolytic uremic syndrome, validating complement blockade for CFH deficiency in non-ocular tissues.

Current intravitreal complement inhibitors slow but do not halt or reverse GA progression — they reduce lesion growth rate by 18-22%, a statistically significant but clinically modest effect. Treatment requires monthly or every-other-month intravitreal injections indefinitely, creating a substantial treatment burden. Both pegcetacoplan and avacincaptad have been associated with increased risk of exudative (wet) AMD conversion and, rarely, retinal vasculitis/occlusive events. For a splice-site variant like c.2596+1G>C that produces systemic CFH deficiency, intravitreal therapy addresses only the ocular manifestation — these patients may also be at risk for CFH-related renal disease (C3 glomerulopathy, aHUS) requiring systemic complement inhibition. No variant-specific clinical trial data exist for rare CFH loss-of-function carriers; efficacy extrapolation from the broader AMD GA population (driven largely by common variants) remains uncertain. Gene therapy to restore CFH expression (AAV-CFH) is being explored preclinically but faces the challenge of sustained secretion of a large complement regulatory protein.

For CFH c.2596+1G>C, a pathogenic splice donor variant that disrupts the C-terminal complement regulatory domains of factor H, systemic or intravitreal anti-complement antibody and aptamer therapies offer a pharmacologically validated approach to slowing geographic atrophy progression. Avacincaptad pegol (Izervay, anti-C5 aptamer, FDA-approved 2023) and pegcetacoplan (Syfovre, anti-C3 antibody fragment, FDA-approved 2023) both reduce GA lesion growth by inhibiting the terminal complement pathway that is overactivated when CFH function is compromised.

CFH is the primary negative regulator of the alternative complement pathway. The c.2596+1G>C variant disrupts the canonical GT splice donor at the exon 17/intron 17 boundary of CFH, likely causing exon skipping or intron retention that truncates or destabilizes the SCR17-20 region responsible for surface complement regulation at Bruch membrane. Loss of CFH surface-binding capacity leads to uncontrolled C3 convertase activity, C3b deposition, membrane attack complex formation, and chronic inflammatory damage to RPE and choriocapillaris. Avacincaptad pegol (anti-C5 aptamer) showed 14% reduction in GA growth rate vs. sham at 12 months in the GATHER2 Phase 3 trial (NCT04435366). Pegcetacoplan (anti-C3) showed 22% reduction at 24 months in OAKS/DERBY Phase 3 trials (NCT03525600/NCT03525613). Both target complement downstream of the CFH deficiency point, making them mechanism-appropriate for CFH loss-of-function carriers. Earlier, lampalizumab (anti-factor D) failed its Phase 3 SPECTRI trial despite initially promising Phase 2 results in CFH risk-allele stratified patients.

Current anti-complement therapies slow but do not halt GA progression — the 14-22% growth rate reduction is modest, and existing vision loss is not reversed. Monthly or bimonthly intravitreal injections impose significant treatment burden and carry risks of endophthalmitis and retinal vasculitis (a noted adverse event with pegcetacoplan). Lampalizumab's Phase 3 failure despite promising Phase 2 biomarker data in CFI/CFH risk-allele carriers is a cautionary tale about complement pharmacogenomic stratification. The c.2596+1G>C variant is rare — trial populations were not enriched for high-impact CFH variants, so the specific benefit in this genotype is extrapolated from mechanism rather than direct evidence. Systemic complement inhibition is not appropriate for a local ocular disease due to infection risk, so intravitreal delivery constraints apply. Whether patients with monogenic CFH deficiency (like this splice variant) derive greater benefit than common-variant polygenic AMD patients has not been studied.

For CFH c.3514G>T (p.Glu1172Ter), a pathogenic nonsense variant in the C-terminal SCR20 domain of complement factor H (CFH) that abolishes cell-surface complement regulation, intravitreal anti-complement antibody/inhibitor therapy represents the most immediately actionable treatment approach. CFH is the primary negative regulator of the alternative complement pathway on host cell surfaces; p.Glu1172Ter truncates the protein before the critical C3b/heparan sulfate binding domain in SCR19-20, eliminating its ability to protect retinal pigment epithelium (RPE) from complement-mediated damage. Pegcetacoplan (Syfovre, targeting C3) and avacincaptad pegol (Izervay, targeting C5) are FDA-approved intravitreal complement inhibitors that directly address the downstream consequence of CFH deficiency — uncontrolled complement activation at the RPE/Bruch membrane interface.

Pegcetacoplan received FDA approval in 2023 for geographic atrophy (GA) secondary to AMD based on the OAKS and DERBY Phase 3 trials, demonstrating a 22% reduction in GA lesion growth over 24 months (Liao et al., Ophthalmology 2024; PMID:37321400). Avacincaptad pegol (anti-C5 aptamer) was approved in 2023 based on the GATHER1/GATHER2 trials showing 35% reduction in GA growth (Jaffe et al., Ophthalmology 2021; PMID:33207274). These approvals validate complement inhibition as a therapeutic strategy for AMD. For CFH p.Glu1172Ter specifically, genetic evidence strongly supports complement dysregulation as the pathogenic mechanism: the CFH locus (1q31.3) harbors the strongest genetic risk factor for AMD (Y402H, rs1061170), and rare CFH loss-of-function variants like p.Glu1172Ter confer high penetrance risk for AMD and related complement-mediated maculopathies. ClinVar classifies this variant as Pathogenic. The SCR20 domain truncated by this variant is essential for CFH binding to glycosaminoglycans on RPE cell surfaces, meaning complement regulation is lost specifically at the retinal target tissue.

Current complement inhibitors slow GA progression but do not reverse existing geographic atrophy or restore lost vision — they are disease-modifying but not curative. Monthly intravitreal injections impose substantial treatment burden. Both pegcetacoplan and avacincaptad pegol carry a signal for increased risk of exudative (wet) AMD conversion, potentially from complement-mediated anti-angiogenic effects being disrupted. These therapies are approved for GA regardless of CFH genotype, so the variant-specific therapeutic advantage for p.Glu1172Ter carriers is primarily in the strength of the mechanistic rationale rather than a unique treatment option. For a null CFH variant like p.Glu1172Ter, systemic complement dysregulation may also predispose to atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy, which intravitreal therapy does not address — systemic complement inhibition with eculizumab or ravulizumab may be needed for renal involvement. Gene replacement (AAV-CFH to RPE) is in preclinical development and could provide continuous local complement regulation without repeated injections, but is years from clinical availability.